Disease · MONDO_0100339
Targets11
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
1 to 11 of 11
Download this page as JSON| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| EPOR | Erythropoietin receptor | 3 | Erythropoietin receptor agonist | Phase 2 | https://conductscience.org/library/genes/2057 | Drugs and targets |
| PPARG | Peroxisome proliferator-activated receptor gamma | 2 | Peroxisome proliferator-activated receptor gamma agonist | Phase 3 | https://conductscience.org/library/genes/5468 | Drugs and targets |
| CHRNA4 | Neuronal acetylcholine receptor; alpha4/beta2 | 1 | Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 partial agonist | Phase 2/3 | https://conductscience.org/library/genes/1137 | Drugs and targets |
| CHRNB2 | Neuronal acetylcholine receptor; alpha4/beta2 | 1 | Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 partial agonist | Phase 2/3 | https://conductscience.org/library/genes/1141 | Drugs and targets |
| HMGCR | 3-hydroxy-3-methylglutaryl-coenzyme A reductase | 1 | HMG-CoA reductase inhibitor | Early phase 1 | https://conductscience.org/library/genes/3156 | Drugs and targets |
| IFNGR1 | Interferon gamma receptor | 1 | Interferon gamma receptor agonist | Phase 3 | https://conductscience.org/library/genes/3459 | Drugs and targets |
| IFNGR2 | Interferon gamma receptor | 1 | Interferon gamma receptor agonist | Phase 3 | https://conductscience.org/library/genes/3460 | Drugs and targets |
| NFE2L2 | Nuclear factor erythroid 2-related factor 2 | 1 | Nuclear factor erythroid 2-related factor 2 activator | Approval | https://conductscience.org/library/genes/4780 | Drugs and targets |
| NQO1 | NAD(P)H dehydrogenase [quinone] 1 | 1 | Quinone reductase 1 modulator | Phase 3 | https://conductscience.org/library/genes/1728 | Drugs and targets |
| NR3C1 | Glucocorticoid receptor | 1 | Glucocorticoid receptor agonist | Early phase 1 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| SNAP25 | Synaptosomal-associated protein 25 | 1 | Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme | Phase 3 | https://conductscience.org/library/genes/6616 | Drugs and targets |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0100339/targets